Normally when you put out a product, you want to take sales away from the competition, not from other products that you sell yourself. But that's exactly what Gilead Sciences (NASDAQ:GILD) is doing, and Motley Fool health care analyst David Williamson thinks it's a great move. Watch the video to find out why.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/18/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
- Why Gilead Sciences Investors Shouldn't Give Up on Remdesivir Just Yet
- 3 Top Dividend Stocks Yielding More Than 4%
- Gilead Sciences (GILD) Q2 2021 Earnings Call Transcript
- Investing $72,036 Into These 3 Stocks Can Generate $300 in Monthly Income for Your Portfolio
- Can Gilead Beat Bristol Myers Squibb With Its Cancer CAR-T Therapy?